HRP20010881A2 - A method for the improvement of transport across adaptable semi-permeable barriers - Google Patents

Info

Publication number

HRP20010881A2

HRP20010881A2 HR20010881A HRP20010881A HRP20010881A2 HR P20010881 A2 HRP20010881 A2 HR P20010881A2 HR 20010881 A HR20010881 A HR 20010881A HR P20010881 A HRP20010881 A HR P20010881A HR P20010881 A2 HRP20010881 A2 HR P20010881A2

Authority

HR

Croatia

Prior art keywords

acid

recommended

mentioned

penetrants

patch

Prior art date

1999-07-05

Links

• Espacenet
• Global Dossier
• Discuss

• 238000000034 method Methods 0.000 title claims description 88
• 230000004888 barrier function Effects 0.000 title claims description 46
• 230000006872 improvement Effects 0.000 title description 2
• -1 carboxymethyl- Chemical group 0.000 claims description 164
• 239000012528 membrane Substances 0.000 claims description 113
• 210000004379 membrane Anatomy 0.000 claims description 112
• 239000000126 substance Substances 0.000 claims description 99
• 150000002632 lipids Chemical class 0.000 claims description 75
• 239000010410 layer Substances 0.000 claims description 74
• 238000002360 preparation method Methods 0.000 claims description 70
• 239000000203 mixture Substances 0.000 claims description 66
• 239000011148 porous material Substances 0.000 claims description 64
• 239000003814 drug Substances 0.000 claims description 52
• 229940079593 drug Drugs 0.000 claims description 47
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Natural products CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 41
• 239000007788 liquid Substances 0.000 claims description 40
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 39
• 238000009472 formulation Methods 0.000 claims description 38
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 36
• 238000002156 mixing Methods 0.000 claims description 36
• 239000003795 chemical substances by application Substances 0.000 claims description 32
• 238000003860 storage Methods 0.000 claims description 30
• 150000003839 salts Chemical class 0.000 claims description 29
• 239000004698 Polyethylene Substances 0.000 claims description 26
• 239000002253 acid Substances 0.000 claims description 25
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 24
• ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 claims description 24
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 24
• BDERNNFJNOPAEC-UHFFFAOYSA-N n-propyl alcohol Natural products CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 24
• 229920000573 polyethylene Polymers 0.000 claims description 24
• 239000004094 surface-active agent Substances 0.000 claims description 24
• 239000004615 ingredient Substances 0.000 claims description 22
• 238000012546 transfer Methods 0.000 claims description 22
• 229920001223 polyethylene glycol Polymers 0.000 claims description 21
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 20
• 230000000694 effects Effects 0.000 claims description 20
• 150000002148 esters Chemical class 0.000 claims description 20
• 239000000243 solution Substances 0.000 claims description 20
• 239000000725 suspension Substances 0.000 claims description 20
• 239000002202 Polyethylene glycol Substances 0.000 claims description 18
• 229960005070 ascorbic acid Drugs 0.000 claims description 16
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 16
• OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 claims description 16
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 16
• 230000002209 hydrophobic effect Effects 0.000 claims description 16
• UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims description 16
• 230000015572 biosynthetic process Effects 0.000 claims description 15
• 238000001914 filtration Methods 0.000 claims description 15
• 239000011159 matrix material Substances 0.000 claims description 15
• QELSKZZBTMNZEB-UHFFFAOYSA-N p-hydroxybenzoic acid propyl ester Natural products CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 15
• 150000003904 phospholipids Chemical class 0.000 claims description 15
• 241000196324 Embryophyta Species 0.000 claims description 14
• 230000009471 action Effects 0.000 claims description 14
• 239000003963 antioxidant agent Substances 0.000 claims description 14
• 235000006708 antioxidants Nutrition 0.000 claims description 14
• 239000004322 Butylated hydroxytoluene Substances 0.000 claims description 13
• NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 13
• 235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 13
• 229940095259 butylated hydroxytoluene Drugs 0.000 claims description 13
• 235000014113 dietary fatty acids Nutrition 0.000 claims description 13
• 238000001704 evaporation Methods 0.000 claims description 13
• 230000008020 evaporation Effects 0.000 claims description 13
• 239000000194 fatty acid Substances 0.000 claims description 13
• 229930195729 fatty acid Natural products 0.000 claims description 13
• 150000003431 steroids Chemical class 0.000 claims description 13
• WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 12
• 241000124008 Mammalia Species 0.000 claims description 12
• BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 claims description 12
• 150000001298 alcohols Chemical class 0.000 claims description 12
• 235000010323 ascorbic acid Nutrition 0.000 claims description 12
• 239000011668 ascorbic acid Substances 0.000 claims description 12
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 12
• QRYRORQUOLYVBU-VBKZILBWSA-N carnosic acid Chemical compound CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims description 12
• 238000002347 injection Methods 0.000 claims description 12
• 239000007924 injection Substances 0.000 claims description 12
• HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 claims description 12
• 230000003641 microbiacidal effect Effects 0.000 claims description 12
• 229940124561 microbicide Drugs 0.000 claims description 12
• 239000002855 microbicide agent Substances 0.000 claims description 12
• 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 12
• WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 12
• 239000000473 propyl gallate Substances 0.000 claims description 12
• 235000010388 propyl gallate Nutrition 0.000 claims description 12
• 229940075579 propyl gallate Drugs 0.000 claims description 12
• 239000004250 tert-Butylhydroquinone Substances 0.000 claims description 12
• 235000019281 tert-butylhydroquinone Nutrition 0.000 claims description 12
• 229930003799 tocopherol Natural products 0.000 claims description 12
• 239000011732 tocopherol Substances 0.000 claims description 12
• 239000012790 adhesive layer Substances 0.000 claims description 11
• 229920000642 polymer Polymers 0.000 claims description 11
• 239000004814 polyurethane Substances 0.000 claims description 11
• 229920002635 polyurethane Polymers 0.000 claims description 10
• 238000002604 ultrasonography Methods 0.000 claims description 10
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
• 150000004665 fatty acids Chemical class 0.000 claims description 9
• 210000004400 mucous membrane Anatomy 0.000 claims description 9
• 230000035515 penetration Effects 0.000 claims description 9
• 239000004417 polycarbonate Substances 0.000 claims description 9
• 229920000515 polycarbonate Polymers 0.000 claims description 9
• 229920000728 polyester Polymers 0.000 claims description 9
• KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 claims description 8
• DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 claims description 8
• WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 claims description 8
• WJXSWCUQABXPFS-UHFFFAOYSA-N 3-hydroxyanthranilic acid Chemical compound NC1=C(O)C=CC=C1C(O)=O WJXSWCUQABXPFS-UHFFFAOYSA-N 0.000 claims description 8
• VCKPUUFAIGNJHC-UHFFFAOYSA-N 3-hydroxykynurenine Chemical compound OC(=O)C(N)CC(=O)C1=CC=CC(O)=C1N VCKPUUFAIGNJHC-UHFFFAOYSA-N 0.000 claims description 8
• CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 claims description 8
• ATMNQRRJNBCQJO-UHFFFAOYSA-N 4-hexoxy-2,3,6-trimethylphenol Chemical compound CCCCCCOC1=CC(C)=C(O)C(C)=C1C ATMNQRRJNBCQJO-UHFFFAOYSA-N 0.000 claims description 8
• UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 claims description 8
• RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 8
• 241000894006 Bacteria Species 0.000 claims description 8
• 239000005711 Benzoic acid Substances 0.000 claims description 8
• BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 claims description 8
• QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 claims description 8
• GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 claims description 8
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 8
• 241000305071 Enterobacterales Species 0.000 claims description 8
• 108010024636 Glutathione Proteins 0.000 claims description 8
• 229930186217 Glycolipid Natural products 0.000 claims description 8
• OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 8
• QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 claims description 8
• 244000270834 Myristica fragrans Species 0.000 claims description 8
• 235000009421 Myristica fragrans Nutrition 0.000 claims description 8
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 8
• 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 8
• 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 8
• 241000191967 Staphylococcus aureus Species 0.000 claims description 8
• 229930182558 Sterol Natural products 0.000 claims description 8
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 8
• 241001148470 aerobic bacillus Species 0.000 claims description 8
• 230000003078 antioxidant effect Effects 0.000 claims description 8
• 244000052616 bacterial pathogen Species 0.000 claims description 8
• 235000010233 benzoic acid Nutrition 0.000 claims description 8
• 235000019282 butylated hydroxyanisole Nutrition 0.000 claims description 8
• 229960003260 chlorhexidine Drugs 0.000 claims description 8
• 229960004926 chlorobutanol Drugs 0.000 claims description 8
• 150000001875 compounds Chemical class 0.000 claims description 8
• DMBHHRLKUKUOEG-UHFFFAOYSA-N diphenylamine Chemical compound C=1C=CC=CC=1NC1=CC=CC=C1 DMBHHRLKUKUOEG-UHFFFAOYSA-N 0.000 claims description 8
• 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 8
• 125000004016 elaidoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])/C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 8
• 210000003038 endothelium Anatomy 0.000 claims description 8
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 8
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
• RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 claims description 8
• 239000000284 extract Substances 0.000 claims description 8
• KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 claims description 8
• 235000001785 ferulic acid Nutrition 0.000 claims description 8
• 229940114124 ferulic acid Drugs 0.000 claims description 8
• KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 claims description 8
• 238000007710 freezing Methods 0.000 claims description 8
• 230000008014 freezing Effects 0.000 claims description 8
• 229960003180 glutathione Drugs 0.000 claims description 8
• LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical compound COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 claims description 8
• ACGUYXCXAPNIKK-UHFFFAOYSA-N hexachlorophene Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(O)C(Cl)=CC(Cl)=C1Cl ACGUYXCXAPNIKK-UHFFFAOYSA-N 0.000 claims description 8
• 229960004068 hexachlorophene Drugs 0.000 claims description 8
• 229920001477 hydrophilic polymer Polymers 0.000 claims description 8
• 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 8
• CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 8
• 229940070765 laurate Drugs 0.000 claims description 8
• LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 8
• 229960002216 methylparaben Drugs 0.000 claims description 8
• 210000004877 mucosa Anatomy 0.000 claims description 8
• 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 8
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 8
• 239000001702 nutmeg Substances 0.000 claims description 8
• 229940049964 oleate Drugs 0.000 claims description 8
• 239000003960 organic solvent Substances 0.000 claims description 8
• 230000003647 oxidation Effects 0.000 claims description 8
• 238000007254 oxidation reaction Methods 0.000 claims description 8
• 150000002989 phenols Chemical class 0.000 claims description 8
• 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 8
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 8
• 229960003415 propylparaben Drugs 0.000 claims description 8
• YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 8
• HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims description 8
• 229940001584 sodium metabisulfite Drugs 0.000 claims description 8
• 235000010262 sodium metabisulphite Nutrition 0.000 claims description 8
• 239000002904 solvent Substances 0.000 claims description 8
• 235000010199 sorbic acid Nutrition 0.000 claims description 8
• 239000004334 sorbic acid Substances 0.000 claims description 8
• 229940075582 sorbic acid Drugs 0.000 claims description 8
• 150000003432 sterols Chemical class 0.000 claims description 8
• 235000003702 sterols Nutrition 0.000 claims description 8
• JMSVCTWVEWCHDZ-UHFFFAOYSA-N syringic acid Chemical compound COC1=CC(C(O)=O)=CC(OC)=C1O JMSVCTWVEWCHDZ-UHFFFAOYSA-N 0.000 claims description 8
• 125000002640 tocopherol group Chemical class 0.000 claims description 8
• 235000019149 tocopherols Nutrition 0.000 claims description 8
• QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 claims description 8
• QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 claims description 8
• DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims description 7
• 238000000576 coating method Methods 0.000 claims description 7
• 229920001296 polysiloxane Polymers 0.000 claims description 7
• 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims description 7
• 239000002562 thickening agent Substances 0.000 claims description 7
• YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 claims description 6
• NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 6
• 125000001931 aliphatic group Chemical group 0.000 claims description 6
• 201000010099 disease Diseases 0.000 claims description 6
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
• 238000002844 melting Methods 0.000 claims description 6
• 230000008018 melting Effects 0.000 claims description 6
• 238000003825 pressing Methods 0.000 claims description 6
• AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims description 6
• 230000001225 therapeutic effect Effects 0.000 claims description 6
• 150000007513 acids Chemical class 0.000 claims description 5
• 150000001649 bromium compounds Chemical class 0.000 claims description 5
• 229940106189 ceramide Drugs 0.000 claims description 5
• 239000011248 coating agent Substances 0.000 claims description 5
• 229910052751 metal Inorganic materials 0.000 claims description 5
• 239000002184 metal Substances 0.000 claims description 5
• 238000012544 monitoring process Methods 0.000 claims description 5
• 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
• FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 5
• 230000036961 partial effect Effects 0.000 claims description 5
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 5
• 229920000053 polysorbate 80 Polymers 0.000 claims description 5
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
• 230000002441 reversible effect Effects 0.000 claims description 5
• 208000017520 skin disease Diseases 0.000 claims description 5
• 238000002791 soaking Methods 0.000 claims description 5
• WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Chemical group CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 claims description 4
• JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 4
• LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 4
• FVNKWWBXNSNIAR-BYPYZUCNSA-N (2s)-2-amino-3-(2-sulfanylidene-1,3-dihydroimidazol-4-yl)propanoic acid Chemical class OC(=O)[C@@H](N)CC1=CNC(=S)N1 FVNKWWBXNSNIAR-BYPYZUCNSA-N 0.000 claims description 4
• LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 claims description 4
• AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical compound O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 claims description 4
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 4
• 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims description 4
• ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 claims description 4
• WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 claims description 4
• WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 claims description 4
• VMMUGOUUBVDDPV-UHFFFAOYSA-N 1,2,3,3a-tetrahydroindeno[1,2-g]indole Chemical compound C1=CC2=C3C=CC=CC3=CC2=C2C1CCN2 VMMUGOUUBVDDPV-UHFFFAOYSA-N 0.000 claims description 4
• CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 claims description 4
• DBHODFSFBXJZNY-UHFFFAOYSA-N 2,4-dichlorobenzyl alcohol Chemical compound OCC1=CC=C(Cl)C=C1Cl DBHODFSFBXJZNY-UHFFFAOYSA-N 0.000 claims description 4
• BIZSVVIRPJXFOI-UHFFFAOYSA-M 2,6-ditert-butyl-4-(2-sulfanylidene-3h-1,3,4-thiadiazol-5-yl)phenolate;2-hydroxyethyl(trimethyl)azanium Chemical compound C[N+](C)(C)CCO.CC(C)(C)C1=C([O-])C(C(C)(C)C)=CC(C=2SC(=S)NN=2)=C1 BIZSVVIRPJXFOI-UHFFFAOYSA-M 0.000 claims description 4
• OJMZIWXMJJGNDC-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-(2-octylphenoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCC1=CC=CC=C1OCCOCCOCCOCCOCCOCCOCCOCCOCCO OJMZIWXMJJGNDC-UHFFFAOYSA-N 0.000 claims description 4
• LRYZPFWEZHSTHD-HEFFAWAOSA-O 2-[[(e,2s,3r)-2-formamido-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical class CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](NC=O)COP(O)(=O)OCC[N+](C)(C)C LRYZPFWEZHSTHD-HEFFAWAOSA-O 0.000 claims description 4
• NBGAYCYFNGPNPV-UHFFFAOYSA-N 2-aminooxybenzoic acid Chemical class NOC1=CC=CC=C1C(O)=O NBGAYCYFNGPNPV-UHFFFAOYSA-N 0.000 claims description 4
• RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 claims description 4
• QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 claims description 4
• CRZGAOZTOAGGTQ-UHFFFAOYSA-N 3-(3,5-ditert-butyl-4-hydroxyphenyl)-[1,3]thiazolo[3,2-b][1,2,4]triazin-7-one Chemical compound CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(C=2N3N=CC(=O)N=C3SC=2)=C1 CRZGAOZTOAGGTQ-UHFFFAOYSA-N 0.000 claims description 4
• CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 claims description 4
• OSDLLIBGSJNGJE-UHFFFAOYSA-N 4-chloro-3,5-dimethylphenol Chemical compound CC1=CC(O)=CC(C)=C1Cl OSDLLIBGSJNGJE-UHFFFAOYSA-N 0.000 claims description 4
• GPGNGBOTUUNOLQ-UHFFFAOYSA-N 4-oxo-2-phenyl-2,3-dihydrochromene-3-carbaldehyde Chemical class O1C2=CC=CC=C2C(=O)C(C=O)C1C1=CC=CC=C1 GPGNGBOTUUNOLQ-UHFFFAOYSA-N 0.000 claims description 4
• GJOHLWZHWQUKAU-UHFFFAOYSA-N 5-azaniumylpentan-2-yl-(6-methoxyquinolin-8-yl)azanium;dihydrogen phosphate Chemical compound OP(O)(O)=O.OP(O)(O)=O.N1=CC=CC2=CC(OC)=CC(NC(C)CCCN)=C21 GJOHLWZHWQUKAU-UHFFFAOYSA-N 0.000 claims description 4
• BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 claims description 4
• XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 claims description 4
• 229920000936 Agarose Polymers 0.000 claims description 4
• 240000002234 Allium sativum Species 0.000 claims description 4
• 241000416162 Astragalus gummifer Species 0.000 claims description 4
• YDAKMIMUVCLFIN-GQCTYLIASA-N Avenanthramide 2 Chemical compound C1=C(O)C(OC)=CC(\C=C\C(\O)=N/C=2C(=CC(O)=C(OC)C=2)C(O)=O)=C1 YDAKMIMUVCLFIN-GQCTYLIASA-N 0.000 claims description 4
• MOZDKDIOPSPTBH-UHFFFAOYSA-N Benzyl parahydroxybenzoate Chemical compound C1=CC(O)=CC=C1C(=O)OCC1=CC=CC=C1 MOZDKDIOPSPTBH-UHFFFAOYSA-N 0.000 claims description 4
• BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims description 4
• 239000004255 Butylated hydroxyanisole Substances 0.000 claims description 4
• YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims description 4
• PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 claims description 4
• 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 4
• XUSYGBPHQBWGAD-PJSUUKDQSA-N Carnosol Chemical compound CC([C@@H]1C2)(C)CCC[C@@]11C(=O)O[C@@H]2C2=C1C(O)=C(O)C(C(C)C)=C2 XUSYGBPHQBWGAD-PJSUUKDQSA-N 0.000 claims description 4
• MMFRMKXYTWBMOM-UHFFFAOYSA-N Carnosol Natural products CCc1cc2C3CC4C(C)(C)CCCC4(C(=O)O3)c2c(O)c1O MMFRMKXYTWBMOM-UHFFFAOYSA-N 0.000 claims description 4
• 102000016938 Catalase Human genes 0.000 claims description 4
• 108010053835 Catalase Proteins 0.000 claims description 4
• NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 claims description 4
• 229920001661 Chitosan Polymers 0.000 claims description 4
• WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 claims description 4
• 244000223760 Cinnamomum zeylanicum Species 0.000 claims description 4
• 102000008186 Collagen Human genes 0.000 claims description 4
• 108010035532 Collagen Proteins 0.000 claims description 4
• AAWZDTNXLSGCEK-UHFFFAOYSA-N Cordycepinsaeure Natural products OC1CC(O)(C(O)=O)CC(O)C1O AAWZDTNXLSGCEK-UHFFFAOYSA-N 0.000 claims description 4
• 244000303965 Cyamopsis psoralioides Species 0.000 claims description 4
• RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 claims description 4
• POYPKGFSZHXASD-WDSKDSINSA-N D-penicillamine disulfide Chemical compound OC(=O)[C@H](N)C(C)(C)SSC(C)(C)[C@@H](N)C(O)=O POYPKGFSZHXASD-WDSKDSINSA-N 0.000 claims description 4
• MDNWOSOZYLHTCG-UHFFFAOYSA-N Dichlorophen Chemical compound OC1=CC=C(Cl)C=C1CC1=CC(Cl)=CC=C1O MDNWOSOZYLHTCG-UHFFFAOYSA-N 0.000 claims description 4
• OJIYIVCMRYCWSE-UHFFFAOYSA-M Domiphen bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CCOC1=CC=CC=C1 OJIYIVCMRYCWSE-UHFFFAOYSA-M 0.000 claims description 4
• AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 claims description 4
• ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 claims description 4
• 229920002079 Ellagic acid Polymers 0.000 claims description 4
• 102000004190 Enzymes Human genes 0.000 claims description 4
• 108090000790 Enzymes Proteins 0.000 claims description 4
• 239000005977 Ethylene Substances 0.000 claims description 4
• PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical class NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims description 4
• 239000005770 Eugenol Substances 0.000 claims description 4
• 108010010803 Gelatin Proteins 0.000 claims description 4
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
• 102000006587 Glutathione peroxidase Human genes 0.000 claims description 4
• 108700016172 Glutathione peroxidases Proteins 0.000 claims description 4
• 108010007979 Glycocholic Acid Proteins 0.000 claims description 4
• 108010035713 Glycodeoxycholic Acid Proteins 0.000 claims description 4
• SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Chemical group CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 4
• 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 4
• 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 4
• 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
• HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 4
• IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical class OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 claims description 4
• PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 4
• 239000002211 L-ascorbic acid Substances 0.000 claims description 4
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical class C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 4
• 235000013628 Lantana involucrata Nutrition 0.000 claims description 4
• XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 claims description 4
• BAVYZALUXZFZLV-UHFFFAOYSA-O Methylammonium ion Chemical class [NH3+]C BAVYZALUXZFZLV-UHFFFAOYSA-O 0.000 claims description 4
• 235000006677 Monarda citriodora ssp. austromontana Nutrition 0.000 claims description 4
• CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims description 4
• 229910002651 NO3 Inorganic materials 0.000 claims description 4
• CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 4
• CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 claims description 4
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 4
• 240000007673 Origanum vulgare Species 0.000 claims description 4
• IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Chemical class OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 claims description 4
• 229920001213 Polysorbate 20 Polymers 0.000 claims description 4
• 229920000153 Povidone-iodine Polymers 0.000 claims description 4
• UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 claims description 4
• AAWZDTNXLSGCEK-ZHQZDSKASA-N Quinic acid Natural products O[C@H]1CC(O)(C(O)=O)C[C@H](O)C1O AAWZDTNXLSGCEK-ZHQZDSKASA-N 0.000 claims description 4
• ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 claims description 4
• 244000178231 Rosmarinus officinalis Species 0.000 claims description 4
• BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 claims description 4
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
• 102000019197 Superoxide Dismutase Human genes 0.000 claims description 4
• 108010012715 Superoxide dismutase Proteins 0.000 claims description 4
• 244000223014 Syzygium aromaticum Species 0.000 claims description 4
• 235000016639 Syzygium aromaticum Nutrition 0.000 claims description 4
• 229920001615 Tragacanth Polymers 0.000 claims description 4
• XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 claims description 4
• 241000209140 Triticum Species 0.000 claims description 4
• 235000021307 Triticum Nutrition 0.000 claims description 4
• GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 claims description 4
• LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims description 4
• TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims description 4
• NWGKJDSIEKMTRX-BFWOXRRGSA-N [(2r)-2-[(3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)C1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-BFWOXRRGSA-N 0.000 claims description 4
• 229960004308 acetylcysteine Drugs 0.000 claims description 4
• 230000002776 aggregation Effects 0.000 claims description 4
• 238000004220 aggregation Methods 0.000 claims description 4
• 229920000615 alginic acid Polymers 0.000 claims description 4
• 235000010443 alginic acid Nutrition 0.000 claims description 4
• 125000000217 alkyl group Chemical group 0.000 claims description 4
• 150000008051 alkyl sulfates Chemical class 0.000 claims description 4
• OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 4
• 125000002714 alpha-linolenoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])[H] 0.000 claims description 4
• 125000000129 anionic group Chemical group 0.000 claims description 4
• 239000003945 anionic surfactant Substances 0.000 claims description 4
• 235000010208 anthocyanin Nutrition 0.000 claims description 4
• 239000004410 anthocyanin Substances 0.000 claims description 4
• 229930002877 anthocyanin Natural products 0.000 claims description 4
• 150000004636 anthocyanins Chemical class 0.000 claims description 4
• 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 claims description 4
• 150000004982 aromatic amines Chemical class 0.000 claims description 4
• 125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 claims description 4
• JXFZHMCSCYADIX-XVNBXDOJSA-N avenanthramide B Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)NC=2C(=CC(O)=CC=2)C(O)=O)=C1 JXFZHMCSCYADIX-XVNBXDOJSA-N 0.000 claims description 4
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 4
• 229960002170 azathioprine Drugs 0.000 claims description 4
• CYDRXTMLKJDRQH-UHFFFAOYSA-N benzododecinium Chemical class CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 claims description 4
• 235000019445 benzyl alcohol Nutrition 0.000 claims description 4
• 229960004217 benzyl alcohol Drugs 0.000 claims description 4
• 229940034794 benzylparaben Drugs 0.000 claims description 4
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
• 235000013734 beta-carotene Nutrition 0.000 claims description 4
• 239000011648 beta-carotene Substances 0.000 claims description 4
• TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 4
• 229960002747 betacarotene Drugs 0.000 claims description 4
• 239000003613 bile acid Substances 0.000 claims description 4
• 230000003115 biocidal effect Effects 0.000 claims description 4
• LRHPLDYGYMQRHN-UHFFFAOYSA-N butyl alcohol Substances CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 4
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
• CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims description 4
• 229940043253 butylated hydroxyanisole Drugs 0.000 claims description 4
• 229940067596 butylparaben Drugs 0.000 claims description 4
• 235000004883 caffeic acid Nutrition 0.000 claims description 4
• 229940074360 caffeic acid Drugs 0.000 claims description 4
• 150000001720 carbohydrates Chemical class 0.000 claims description 4
• 235000014633 carbohydrates Nutrition 0.000 claims description 4
• 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 4
• 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
• 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 4
• 235000004654 carnosol Nutrition 0.000 claims description 4
• 229920001525 carrageenan Polymers 0.000 claims description 4
• 235000010418 carrageenan Nutrition 0.000 claims description 4
• 239000003093 cationic surfactant Substances 0.000 claims description 4
• 229920002678 cellulose Polymers 0.000 claims description 4
• 239000001913 cellulose Substances 0.000 claims description 4
• ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims description 4
• 229930183167 cerebroside Natural products 0.000 claims description 4
• 150000001784 cerebrosides Chemical class 0.000 claims description 4
• YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 claims description 4
• 229960001927 cetylpyridinium chloride Drugs 0.000 claims description 4
• RLGQACBPNDBWTB-UHFFFAOYSA-N cetyltrimethylammonium ion Chemical class CCCCCCCCCCCCCCCC[N+](C)(C)C RLGQACBPNDBWTB-UHFFFAOYSA-N 0.000 claims description 4
• 239000002738 chelating agent Substances 0.000 claims description 4
• WSURYVQLWPAKRH-CMDGGOBGSA-N chembl356510 Chemical compound N1C(C)=CC(\C=C\C=2C=C(C(O)=C(C=2)C(C)(C)C)C(C)(C)C)=N1 WSURYVQLWPAKRH-CMDGGOBGSA-N 0.000 claims description 4
• 150000001805 chlorine compounds Chemical class 0.000 claims description 4
• HEZQRPHEDDAJTF-UHFFFAOYSA-N chloro(phenyl)methanol Chemical compound OC(Cl)C1=CC=CC=C1 HEZQRPHEDDAJTF-UHFFFAOYSA-N 0.000 claims description 4
• 229940074393 chlorogenic acid Drugs 0.000 claims description 4
• 235000001368 chlorogenic acid Nutrition 0.000 claims description 4
• CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 claims description 4
• FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 claims description 4
• 229960003677 chloroquine Drugs 0.000 claims description 4
• WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 claims description 4
• 235000013985 cinnamic acid Nutrition 0.000 claims description 4
• 229930016911 cinnamic acid Natural products 0.000 claims description 4
• 235000017803 cinnamon Nutrition 0.000 claims description 4
• BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 claims description 4
• QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 claims description 4
• 229920001436 collagen Polymers 0.000 claims description 4
• 239000012141 concentrate Substances 0.000 claims description 4
• 229920001577 copolymer Polymers 0.000 claims description 4
• 125000000332 coumarinyl group Chemical class O1C(=O)C(=CC2=CC=CC=C12)* 0.000 claims description 4
• 229930003836 cresol Natural products 0.000 claims description 4
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 4
• 235000018417 cysteine Nutrition 0.000 claims description 4
• GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
• 230000006378 damage Effects 0.000 claims description 4
• 229940009976 deoxycholate Drugs 0.000 claims description 4
• KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims description 4
• 229960003964 deoxycholic acid Drugs 0.000 claims description 4
• 229940099217 desferal Drugs 0.000 claims description 4
• IDDIJAWJANBQLJ-UHFFFAOYSA-N desferrioxamine B mesylate Chemical compound [H+].CS([O-])(=O)=O.CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN IDDIJAWJANBQLJ-UHFFFAOYSA-N 0.000 claims description 4
• 238000000502 dialysis Methods 0.000 claims description 4
• 229960004698 dichlorobenzyl alcohol Drugs 0.000 claims description 4
• 229960003887 dichlorophen Drugs 0.000 claims description 4
• 229960001259 diclofenac Drugs 0.000 claims description 4
• DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 4
• HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 claims description 4
• 229960000616 diflunisal Drugs 0.000 claims description 4
• 238000010790 dilution Methods 0.000 claims description 4
• 239000012895 dilution Substances 0.000 claims description 4
• 150000002019 disulfides Chemical class 0.000 claims description 4
• SYELZBGXAIXKHU-UHFFFAOYSA-N dodecyldimethylamine N-oxide Chemical compound CCCCCCCCCCCC[N+](C)(C)[O-] SYELZBGXAIXKHU-UHFFFAOYSA-N 0.000 claims description 4
• 229960002852 ellagic acid Drugs 0.000 claims description 4
• 235000004132 ellagic acid Nutrition 0.000 claims description 4
• 230000002255 enzymatic effect Effects 0.000 claims description 4
• HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 claims description 4
• 125000004185 ester group Chemical group 0.000 claims description 4
• 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 4
• 239000005038 ethylene vinyl acetate Substances 0.000 claims description 4
• 229960002217 eugenol Drugs 0.000 claims description 4
• 229930003944 flavone Natural products 0.000 claims description 4
• 150000002213 flavones Chemical class 0.000 claims description 4
• 235000011949 flavones Nutrition 0.000 claims description 4
• 229930003935 flavonoid Natural products 0.000 claims description 4
• YTAQZPGBTPDBPW-UHFFFAOYSA-N flavonoid group Chemical class O1C(C(C(=O)C2=CC=CC=C12)=O)C1=CC=CC=C1 YTAQZPGBTPDBPW-UHFFFAOYSA-N 0.000 claims description 4
• 150000002215 flavonoids Chemical class 0.000 claims description 4
• 235000017173 flavonoids Nutrition 0.000 claims description 4
• HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 claims description 4
• 150000002216 flavonol derivatives Chemical class 0.000 claims description 4
• 235000011957 flavonols Nutrition 0.000 claims description 4
• 235000013312 flour Nutrition 0.000 claims description 4
• 229960004369 flufenamic acid Drugs 0.000 claims description 4
• LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 claims description 4
• 239000006260 foam Substances 0.000 claims description 4
• 150000002270 gangliosides Chemical class 0.000 claims description 4
• 235000004611 garlic Nutrition 0.000 claims description 4
• 239000007789 gas Substances 0.000 claims description 4
• 229920000159 gelatin Polymers 0.000 claims description 4
• 235000019322 gelatine Nutrition 0.000 claims description 4
• 235000011852 gelatine desserts Nutrition 0.000 claims description 4
• 229960005219 gentisic acid Drugs 0.000 claims description 4
• 229940050410 gluconate Drugs 0.000 claims description 4
• 239000008103 glucose Substances 0.000 claims description 4
• 125000005456 glyceride group Chemical group 0.000 claims description 4
• RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 claims description 4
• WVULKSPCQVQLCU-BUXLTGKBSA-N glycodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 WVULKSPCQVQLCU-BUXLTGKBSA-N 0.000 claims description 4
• 150000002339 glycosphingolipids Chemical class 0.000 claims description 4
• 229960001867 guaiacol Drugs 0.000 claims description 4
• 229920002674 hyaluronan Polymers 0.000 claims description 4
• 229910052739 hydrogen Inorganic materials 0.000 claims description 4
• 239000001257 hydrogen Substances 0.000 claims description 4
• 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
• XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 claims description 4
• 229960004171 hydroxychloroquine Drugs 0.000 claims description 4
• 229930005346 hydroxycinnamic acid Natural products 0.000 claims description 4
• DEDGUGJNLNLJSR-UHFFFAOYSA-N hydroxycinnamic acid group Chemical class OC(C(=O)O)=CC1=CC=CC=C1 DEDGUGJNLNLJSR-UHFFFAOYSA-N 0.000 claims description 4
• 235000010359 hydroxycinnamic acids Nutrition 0.000 claims description 4
• 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 4
• 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
• 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 4
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
• UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 4
• 229960001680 ibuprofen Drugs 0.000 claims description 4
• 229960000905 indomethacin Drugs 0.000 claims description 4
• CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical group O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 4
• 229960000367 inositol Drugs 0.000 claims description 4
• 229960004592 isopropanol Drugs 0.000 claims description 4
• DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims description 4
• 229960000991 ketoprofen Drugs 0.000 claims description 4
• 229940049918 linoleate Drugs 0.000 claims description 4
• 125000005644 linolenyl group Chemical group 0.000 claims description 4
• 125000005645 linoleyl group Chemical group 0.000 claims description 4
• 239000007791 liquid phase Substances 0.000 claims description 4
• 229960003951 masoprocol Drugs 0.000 claims description 4
• 229960003464 mefenamic acid Drugs 0.000 claims description 4
• HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 claims description 4
• 229960000901 mepacrine Drugs 0.000 claims description 4
• 150000002731 mercury compounds Chemical class 0.000 claims description 4
• 229960004635 mesna Drugs 0.000 claims description 4
• 150000002734 metacrylic acid derivatives Chemical class 0.000 claims description 4
• CYEBJEDOHLIWNP-UHFFFAOYSA-N methanethioamide Chemical class NC=S CYEBJEDOHLIWNP-UHFFFAOYSA-N 0.000 claims description 4
• 229920000609 methyl cellulose Polymers 0.000 claims description 4
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 4
• 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 4
• WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 claims description 4
• 235000010981 methylcellulose Nutrition 0.000 claims description 4
• 239000001923 methylcellulose Substances 0.000 claims description 4
• 229960002900 methylcellulose Drugs 0.000 claims description 4
• FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 claims description 4
• 230000004048 modification Effects 0.000 claims description 4
• 238000012986 modification Methods 0.000 claims description 4
• PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 claims description 4
• 229940105132 myristate Drugs 0.000 claims description 4
• 229940078490 n,n-dimethylglycine Drugs 0.000 claims description 4
• 229960002009 naproxen Drugs 0.000 claims description 4
• CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 4
• 229920001206 natural gum Polymers 0.000 claims description 4
• VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims description 4
• 239000002736 nonionic surfactant Substances 0.000 claims description 4
• 229960000649 oxyphenbutazone Drugs 0.000 claims description 4
• HFHZKZSRXITVMK-UHFFFAOYSA-N oxyphenbutazone Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 HFHZKZSRXITVMK-UHFFFAOYSA-N 0.000 claims description 4
• 125000001236 palmitoleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
• 229960005489 paracetamol Drugs 0.000 claims description 4
• 239000001814 pectin Substances 0.000 claims description 4
• 235000010987 pectin Nutrition 0.000 claims description 4
• 229920001277 pectin Polymers 0.000 claims description 4
• 229960001639 penicillamine Drugs 0.000 claims description 4
• 239000012071 phase Substances 0.000 claims description 4
• DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 claims description 4
• 229960002695 phenobarbital Drugs 0.000 claims description 4
• 150000007965 phenolic acids Chemical class 0.000 claims description 4
• 239000002530 phenolic antioxidant Substances 0.000 claims description 4
• 229960002895 phenylbutazone Drugs 0.000 claims description 4
• VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 claims description 4
• 150000008105 phosphatidylcholines Chemical class 0.000 claims description 4
• 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 4
• 229940067605 phosphatidylethanolamines Drugs 0.000 claims description 4
• 229940067626 phosphatidylinositols Drugs 0.000 claims description 4
• 150000003905 phosphatidylinositols Chemical class 0.000 claims description 4
• 150000008106 phosphatidylserines Chemical class 0.000 claims description 4
• 239000000467 phytic acid Chemical class 0.000 claims description 4
• 235000002949 phytic acid Nutrition 0.000 claims description 4
• 229940068041 phytic acid Drugs 0.000 claims description 4
• 229960002702 piroxicam Drugs 0.000 claims description 4
• QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims description 4
• 229920001983 poloxamer Polymers 0.000 claims description 4
• 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims description 4
• 229920000058 polyacrylate Polymers 0.000 claims description 4
• 229920002239 polyacrylonitrile Polymers 0.000 claims description 4
• 229920000671 polyethylene glycol diacrylate Polymers 0.000 claims description 4
• 229920000193 polymethacrylate Polymers 0.000 claims description 4
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 4
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 4
• 229920001184 polypeptide Polymers 0.000 claims description 4
• 229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
• 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 4
• 229960001621 povidone-iodine Drugs 0.000 claims description 4
• 229960005179 primaquine Drugs 0.000 claims description 4
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
• 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 4
• 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 4
• QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims description 4
• 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 4
• 150000003856 quaternary ammonium compounds Chemical class 0.000 claims description 4
• GPKJTRJOBQGKQK-UHFFFAOYSA-N quinacrine Chemical compound C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 GPKJTRJOBQGKQK-UHFFFAOYSA-N 0.000 claims description 4
• DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 claims description 4
• TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 claims description 4
• 235000002020 sage Nutrition 0.000 claims description 4
• 229960004889 salicylic acid Drugs 0.000 claims description 4
• CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Chemical group OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 4
• BTURAGWYSMTVOW-UHFFFAOYSA-M sodium dodecanoate Chemical compound [Na+].CCCCCCCCCCCC([O-])=O BTURAGWYSMTVOW-UHFFFAOYSA-M 0.000 claims description 4
• VMSNAUAEKXEYGP-YEUHZSMFSA-M sodium glycodeoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 VMSNAUAEKXEYGP-YEUHZSMFSA-M 0.000 claims description 4
• 229940082004 sodium laurate Drugs 0.000 claims description 4
• 229940104256 sodium taurate Drugs 0.000 claims description 4
• WYPBVHPKMJYUEO-NBTZWHCOSA-M sodium;(9z,12z)-octadeca-9,12-dienoate Chemical compound [Na+].CCCCC\C=C/C\C=C/CCCCCCCC([O-])=O WYPBVHPKMJYUEO-NBTZWHCOSA-M 0.000 claims description 4
• BCKXLBQYZLBQEK-RRABGKBLSA-M sodium;(e)-octadec-9-enoate Chemical compound [Na+].CCCCCCCC\C=C\CCCCCCCC([O-])=O BCKXLBQYZLBQEK-RRABGKBLSA-M 0.000 claims description 4
• GWLWWNLFFNJPDP-UHFFFAOYSA-M sodium;2-aminoethanesulfonate Chemical compound [Na+].NCCS([O-])(=O)=O GWLWWNLFFNJPDP-UHFFFAOYSA-M 0.000 claims description 4
• 229940035044 sorbitan monolaurate Drugs 0.000 claims description 4
• 239000001593 sorbitan monooleate Substances 0.000 claims description 4
• 229940035049 sorbitan monooleate Drugs 0.000 claims description 4
• WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical group CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 claims description 4
• 150000003410 sphingosines Chemical class 0.000 claims description 4
• 235000013599 spices Nutrition 0.000 claims description 4
• 238000005507 spraying Methods 0.000 claims description 4
• 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
• 229940117986 sulfobetaine Drugs 0.000 claims description 4
• 150000003462 sulfoxides Chemical class 0.000 claims description 4
• 229910052717 sulfur Inorganic materials 0.000 claims description 4
• 239000011593 sulfur Substances 0.000 claims description 4
• 208000011580 syndromic disease Diseases 0.000 claims description 4
• YIBXWXOYFGZLRU-UHFFFAOYSA-N syringic aldehyde Natural products CC12CCC(C3(CCC(=O)C(C)(C)C3CC=3)C)C=3C1(C)CCC2C1COC(C)(C)C(O)C(O)C1 YIBXWXOYFGZLRU-UHFFFAOYSA-N 0.000 claims description 4
• 235000018553 tannin Nutrition 0.000 claims description 4
• 229920001864 tannin Polymers 0.000 claims description 4
• 239000001648 tannin Substances 0.000 claims description 4
• WBWWGRHZICKQGZ-HZAMXZRMSA-M taurocholate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 WBWWGRHZICKQGZ-HZAMXZRMSA-M 0.000 claims description 4
• AWDRATDZQPNJFN-VAYUFCLWSA-N taurodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 AWDRATDZQPNJFN-VAYUFCLWSA-N 0.000 claims description 4
• RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 claims description 4
• 150000003568 thioethers Chemical class 0.000 claims description 4
• 229960004906 thiomersal Drugs 0.000 claims description 4
• 235000010384 tocopherol Nutrition 0.000 claims description 4
• 229960001295 tocopherol Drugs 0.000 claims description 4
• 235000010487 tragacanth Nutrition 0.000 claims description 4
• 150000003852 triazoles Chemical class 0.000 claims description 4
• 229960003500 triclosan Drugs 0.000 claims description 4
• QNTNKSLOFHEFPK-UPTCCGCDSA-N ubiquinol-10 Chemical compound COC1=C(O)C(C)=C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C(O)=C1OC QNTNKSLOFHEFPK-UPTCCGCDSA-N 0.000 claims description 4
• 125000005314 unsaturated fatty acid group Chemical group 0.000 claims description 4
• 229940116269 uric acid Drugs 0.000 claims description 4
• MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 claims description 4
• 235000012141 vanillin Nutrition 0.000 claims description 4
• FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 claims description 4
• 229920001285 xanthan gum Polymers 0.000 claims description 4
• 239000002888 zwitterionic surfactant Substances 0.000 claims description 4
• GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 4
• OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 4
• METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 claims description 3
• KOHIRBRYDXPAMZ-YHBROIRLSA-N (S,R,R,R)-nebivolol Chemical compound C1CC2=CC(F)=CC=C2O[C@H]1[C@H](O)CNC[C@@H](O)[C@H]1OC2=CC=C(F)C=C2CC1 KOHIRBRYDXPAMZ-YHBROIRLSA-N 0.000 claims description 3
• ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 claims description 3
• JCIIKRHCWVHVFF-UHFFFAOYSA-N 1,2,4-thiadiazol-5-amine;hydrochloride Chemical compound Cl.NC1=NC=NS1 JCIIKRHCWVHVFF-UHFFFAOYSA-N 0.000 claims description 3
• SKDGWNHUETZZCS-UHFFFAOYSA-N 2,3-ditert-butylphenol Chemical compound CC(C)(C)C1=CC=CC(O)=C1C(C)(C)C SKDGWNHUETZZCS-UHFFFAOYSA-N 0.000 claims description 3
• UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 claims description 3
• 108010088751 Albumins Proteins 0.000 claims description 3
• ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 claims description 3
• CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 3
• 229940127291 Calcium channel antagonist Drugs 0.000 claims description 3
• 241000499489 Castor canadensis Species 0.000 claims description 3
• 108010075016 Ceruloplasmin Proteins 0.000 claims description 3
• 102100023321 Ceruloplasmin Human genes 0.000 claims description 3
• 206010048768 Dermatosis Diseases 0.000 claims description 3
• 102000008857 Ferritin Human genes 0.000 claims description 3
• 108050000784 Ferritin Proteins 0.000 claims description 3
• 238000008416 Ferritin Methods 0.000 claims description 3
• 102000014702 Haptoglobin Human genes 0.000 claims description 3
• 108050005077 Haptoglobin Proteins 0.000 claims description 3
• 102000013271 Hemopexin Human genes 0.000 claims description 3
• 108010026027 Hemopexin Proteins 0.000 claims description 3
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 3
• 102000010445 Lactoferrin Human genes 0.000 claims description 3
• 108010063045 Lactoferrin Proteins 0.000 claims description 3
• 235000011779 Menyanthes trifoliata Nutrition 0.000 claims description 3
• ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 claims description 3
• FAIIFDPAEUKBEP-UHFFFAOYSA-N Nilvadipine Chemical compound COC(=O)C1=C(C#N)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+]([O-])=O)=C1 FAIIFDPAEUKBEP-UHFFFAOYSA-N 0.000 claims description 3
• 229920002367 Polyisobutene Polymers 0.000 claims description 3
• 102000004338 Transferrin Human genes 0.000 claims description 3
• 108090000901 Transferrin Proteins 0.000 claims description 3
• JBDGDEWWOUBZPM-XYPYZODXSA-N ambroxol Chemical compound NC1=C(Br)C=C(Br)C=C1CN[C@@H]1CC[C@@H](O)CC1 JBDGDEWWOUBZPM-XYPYZODXSA-N 0.000 claims description 3
• 229960005174 ambroxol Drugs 0.000 claims description 3
• 229960005260 amiodarone Drugs 0.000 claims description 3
• 230000003288 anthiarrhythmic effect Effects 0.000 claims description 3
• 239000003416 antiarrhythmic agent Substances 0.000 claims description 3
• NZLBHDRPUJLHCE-UHFFFAOYSA-N aprindine Chemical compound C1C2=CC=CC=C2CC1N(CCCN(CC)CC)C1=CC=CC=C1 NZLBHDRPUJLHCE-UHFFFAOYSA-N 0.000 claims description 3
• 229960004957 aprindine Drugs 0.000 claims description 3
• 229960002274 atenolol Drugs 0.000 claims description 3
• 239000002876 beta blocker Substances 0.000 claims description 3
• 229940099352 cholate Drugs 0.000 claims description 3
• 230000007123 defense Effects 0.000 claims description 3
• 150000002191 fatty alcohols Chemical class 0.000 claims description 3
• 239000000017 hydrogel Substances 0.000 claims description 3
• 210000003734 kidney Anatomy 0.000 claims description 3
• CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims description 3
• 229940078795 lactoferrin Drugs 0.000 claims description 3
• 235000021242 lactoferrin Nutrition 0.000 claims description 3
• 229960000485 methotrexate Drugs 0.000 claims description 3
• VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 claims description 3
• 229960000619 nebivolol Drugs 0.000 claims description 3
• 229960001783 nicardipine Drugs 0.000 claims description 3
• HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims description 3
• 229960001597 nifedipine Drugs 0.000 claims description 3
• 229960005366 nilvadipine Drugs 0.000 claims description 3
• 229960000715 nimodipine Drugs 0.000 claims description 3
• 229960000227 nisoldipine Drugs 0.000 claims description 3
• 230000003204 osmotic effect Effects 0.000 claims description 3
• 235000009048 phenolic acids Nutrition 0.000 claims description 3
• 229940096826 phenylmercuric acetate Drugs 0.000 claims description 3
• 229960000247 phenylmercuric borate Drugs 0.000 claims description 3
• 150000008103 phosphatidic acids Chemical class 0.000 claims description 3
• 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
• FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 claims description 3
• 229960003912 probucol Drugs 0.000 claims description 3
• 229960003712 propranolol Drugs 0.000 claims description 3
• 235000011069 sorbitan monooleate Nutrition 0.000 claims description 3
• 229960001603 tamoxifen Drugs 0.000 claims description 3
• 239000012581 transferrin Substances 0.000 claims description 3
• 208000005676 Adrenogenital syndrome Diseases 0.000 claims description 2
• 201000004384 Alopecia Diseases 0.000 claims description 2
• 208000032467 Aplastic anaemia Diseases 0.000 claims description 2
• 208000027496 Behcet disease Diseases 0.000 claims description 2
• 208000009137 Behcet syndrome Diseases 0.000 claims description 2
• 208000003014 Bites and Stings Diseases 0.000 claims description 2
• 208000019838 Blood disease Diseases 0.000 claims description 2
• 208000020084 Bone disease Diseases 0.000 claims description 2
• 206010048962 Brain oedema Diseases 0.000 claims description 2
• 208000002177 Cataract Diseases 0.000 claims description 2
• 208000010007 Cogan syndrome Diseases 0.000 claims description 2
• 208000008448 Congenital adrenal hyperplasia Diseases 0.000 claims description 2
• 201000004624 Dermatitis Diseases 0.000 claims description 2
• 206010060742 Endocrine ophthalmopathy Diseases 0.000 claims description 2
• 206010014950 Eosinophilia Diseases 0.000 claims description 2
• 206010015218 Erythema multiforme Diseases 0.000 claims description 2
• 208000018522 Gastrointestinal disease Diseases 0.000 claims description 2
• 101710154606 Hemagglutinin Proteins 0.000 claims description 2
• 206010019663 Hepatic failure Diseases 0.000 claims description 2
• 206010019973 Herpes virus infection Diseases 0.000 claims description 2
• 208000037147 Hypercalcaemia Diseases 0.000 claims description 2
• 206010021074 Hypoplastic anaemia Diseases 0.000 claims description 2
• 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
• 208000011200 Kawasaki disease Diseases 0.000 claims description 2
• 206010028813 Nausea Diseases 0.000 claims description 2
• 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 2
• 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 2
• 208000002193 Pain Diseases 0.000 claims description 2
• 206010033645 Pancreatitis Diseases 0.000 claims description 2
• 206010034277 Pemphigoid Diseases 0.000 claims description 2
• 241000721454 Pemphigus Species 0.000 claims description 2
• 208000007048 Polymyalgia Rheumatica Diseases 0.000 claims description 2
• 206010036105 Polyneuropathy Diseases 0.000 claims description 2
• 206010036376 Postherpetic Neuralgia Diseases 0.000 claims description 2
• 101710176177 Protein A56 Proteins 0.000 claims description 2
• 201000004681 Psoriasis Diseases 0.000 claims description 2
• 208000006311 Pyoderma Diseases 0.000 claims description 2
• 208000001647 Renal Insufficiency Diseases 0.000 claims description 2
• 201000001949 Retinal Vasculitis Diseases 0.000 claims description 2
• 206010039705 Scleritis Diseases 0.000 claims description 2
• 206010043561 Thrombocytopenic purpura Diseases 0.000 claims description 2
• 208000024780 Urticaria Diseases 0.000 claims description 2
• 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 2
• 210000004100 adrenal gland Anatomy 0.000 claims description 2
• 231100000360 alopecia Toxicity 0.000 claims description 2
• 208000006673 asthma Diseases 0.000 claims description 2
• 208000010668 atopic eczema Diseases 0.000 claims description 2
• 210000004204 blood vessel Anatomy 0.000 claims description 2
• 208000006752 brain edema Diseases 0.000 claims description 2
• 208000018631 connective tissue disease Diseases 0.000 claims description 2
• 201000001981 dermatomyositis Diseases 0.000 claims description 2
• 239000002274 desiccant Substances 0.000 claims description 2
• 239000006185 dispersion Substances 0.000 claims description 2
• 206010015037 epilepsy Diseases 0.000 claims description 2
• 210000003238 esophagus Anatomy 0.000 claims description 2
• 208000030533 eye disease Diseases 0.000 claims description 2
• 239000000185 hemagglutinin Substances 0.000 claims description 2
• 201000011066 hemangioma Diseases 0.000 claims description 2
• 208000014951 hematologic disease Diseases 0.000 claims description 2
• 208000018706 hematopoietic system disease Diseases 0.000 claims description 2
• 208000007475 hemolytic anemia Diseases 0.000 claims description 2
• 230000000148 hypercalcaemia Effects 0.000 claims description 2
• 208000030915 hypercalcemia disease Diseases 0.000 claims description 2
• 230000028993 immune response Effects 0.000 claims description 2
• 208000015181 infectious disease Diseases 0.000 claims description 2
• 201000006747 infectious mononucleosis Diseases 0.000 claims description 2
• 208000027866 inflammatory disease Diseases 0.000 claims description 2
• 201000006370 kidney failure Diseases 0.000 claims description 2
• 208000007903 liver failure Diseases 0.000 claims description 2
• 231100000835 liver failure Toxicity 0.000 claims description 2
• 206010025135 lupus erythematosus Diseases 0.000 claims description 2
• 201000000564 macroglobulinemia Diseases 0.000 claims description 2
• 239000012982 microporous membrane Substances 0.000 claims description 2
• 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims description 2
• 206010028417 myasthenia gravis Diseases 0.000 claims description 2
• 230000008693 nausea Effects 0.000 claims description 2
• 201000001119 neuropathy Diseases 0.000 claims description 2
• 230000007823 neuropathy Effects 0.000 claims description 2
• 201000008482 osteoarthritis Diseases 0.000 claims description 2
• 238000004806 packaging method and process Methods 0.000 claims description 2
• 230000036407 pain Effects 0.000 claims description 2
• 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
• 208000005987 polymyositis Diseases 0.000 claims description 2
• 230000007824 polyneuropathy Effects 0.000 claims description 2
• 239000011241 protective layer Substances 0.000 claims description 2
• 208000023504 respiratory system disease Diseases 0.000 claims description 2
• 206010039083 rhinitis Diseases 0.000 claims description 2
• 201000000306 sarcoidosis Diseases 0.000 claims description 2
• 210000001685 thyroid gland Anatomy 0.000 claims description 2
• GLZWNFNQMJAZGY-UHFFFAOYSA-N octaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCO GLZWNFNQMJAZGY-UHFFFAOYSA-N 0.000 claims 2
• 230000004936 stimulating effect Effects 0.000 claims 2
• 102100027211 Albumin Human genes 0.000 claims 1
• 235000005979 Citrus limon Nutrition 0.000 claims 1
• 244000131522 Citrus pyriformis Species 0.000 claims 1
• 230000008034 disappearance Effects 0.000 claims 1
• 210000003491 skin Anatomy 0.000 description 129
• MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 11
• 239000013543 active substance Substances 0.000 description 11
• 210000000434 stratum corneum Anatomy 0.000 description 10
• 239000000853 adhesive Substances 0.000 description 9
• 230000001070 adhesive effect Effects 0.000 description 9
• 239000007933 dermal patch Substances 0.000 description 9
• 238000009826 distribution Methods 0.000 description 9
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
• 210000004369 blood Anatomy 0.000 description 8
• 239000008280 blood Substances 0.000 description 8
• 210000004027 cell Anatomy 0.000 description 8
• 230000008569 process Effects 0.000 description 8
• 241001465754 Metazoa Species 0.000 description 7
• 239000000463 material Substances 0.000 description 7
• 210000000056 organ Anatomy 0.000 description 7
• 238000012360 testing method Methods 0.000 description 7
• VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 6
• 239000003623 enhancer Substances 0.000 description 6
• 238000011049 filling Methods 0.000 description 6
• 230000036571 hydration Effects 0.000 description 6
• 238000006703 hydration reaction Methods 0.000 description 6
• 238000005304 joining Methods 0.000 description 6
• 238000009740 moulding (composite fabrication) Methods 0.000 description 6
• 210000001519 tissue Anatomy 0.000 description 6
• 239000004820 Pressure-sensitive adhesive Substances 0.000 description 5
• 230000005540 biological transmission Effects 0.000 description 5
• 230000008859 change Effects 0.000 description 5
• 238000010586 diagram Methods 0.000 description 5
• 238000009792 diffusion process Methods 0.000 description 5
• 229960005309 estradiol Drugs 0.000 description 5
• 229930182833 estradiol Natural products 0.000 description 5
• 238000002474 experimental method Methods 0.000 description 5
• 235000018102 proteins Nutrition 0.000 description 5
• 102000004169 proteins and genes Human genes 0.000 description 5
• 108090000623 proteins and genes Proteins 0.000 description 5
• 229960003604 testosterone Drugs 0.000 description 5
• 230000037317 transdermal delivery Effects 0.000 description 5
• SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 4
• 239000000969 carrier Substances 0.000 description 4
• 238000012377 drug delivery Methods 0.000 description 4
• 230000033001 locomotion Effects 0.000 description 4
• 230000035699 permeability Effects 0.000 description 4
• 239000008363 phosphate buffer Substances 0.000 description 4
• WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 4
• 230000008591 skin barrier function Effects 0.000 description 4
• 231100000245 skin permeability Toxicity 0.000 description 4
• NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 4
• 239000000006 Nitroglycerin Substances 0.000 description 3
• 210000000736 corneocyte Anatomy 0.000 description 3
• 239000003599 detergent Substances 0.000 description 3
• 238000004090 dissolution Methods 0.000 description 3
• 210000002615 epidermis Anatomy 0.000 description 3
• 239000012530 fluid Substances 0.000 description 3
• 229960003711 glyceryl trinitrate Drugs 0.000 description 3
• 210000004185 liver Anatomy 0.000 description 3
• 238000005259 measurement Methods 0.000 description 3
• 230000037361 pathway Effects 0.000 description 3
• 238000011084 recovery Methods 0.000 description 3
• 230000002829 reductive effect Effects 0.000 description 3
• 238000007789 sealing Methods 0.000 description 3
• 238000013271 transdermal drug delivery Methods 0.000 description 3
• BWRYNNCGEDOTRW-GXDHUFHOSA-N (4e)-4-[(3,5-ditert-butyl-4-hydroxyphenyl)methylidene]-2-methyloxazinan-3-one Chemical compound O=C1N(C)OCC\C1=C/C1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 BWRYNNCGEDOTRW-GXDHUFHOSA-N 0.000 description 2
• 102000009027 Albumins Human genes 0.000 description 2
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
• 229920000742 Cotton Polymers 0.000 description 2
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
• 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 2
• 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
• 241000699670 Mus sp. Species 0.000 description 2
• WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
• 239000004480 active ingredient Substances 0.000 description 2
• 230000003044 adaptive effect Effects 0.000 description 2
• 238000004026 adhesive bonding Methods 0.000 description 2
• 244000309464 bull Species 0.000 description 2
• BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical class C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 2
• 238000006731 degradation reaction Methods 0.000 description 2
• 231100000673 dose–response relationship Toxicity 0.000 description 2
• 210000003743 erythrocyte Anatomy 0.000 description 2
• PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 2
• 230000005661 hydrophobic surface Effects 0.000 description 2
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
• 230000008776 intercellular pathway Effects 0.000 description 2
• 210000002510 keratinocyte Anatomy 0.000 description 2
• 230000000670 limiting effect Effects 0.000 description 2
• 230000007774 longterm Effects 0.000 description 2
• 230000014759 maintenance of location Effects 0.000 description 2
• 238000004519 manufacturing process Methods 0.000 description 2
• 210000004779 membrane envelope Anatomy 0.000 description 2
• 238000005192 partition Methods 0.000 description 2
• 239000003961 penetration enhancing agent Substances 0.000 description 2
• VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
• 229920000098 polyolefin Polymers 0.000 description 2
• 230000001681 protective effect Effects 0.000 description 2
• 238000011160 research Methods 0.000 description 2
• STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 2
• 210000004927 skin cell Anatomy 0.000 description 2
• 230000009885 systemic effect Effects 0.000 description 2
• 238000010257 thawing Methods 0.000 description 2
• SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
• DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
• 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
• NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
• GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
• 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 1
• POPFMWWJOGLOIF-XWCQMRHXSA-N Flurandrenolide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O POPFMWWJOGLOIF-XWCQMRHXSA-N 0.000 description 1
• STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
• 206010020649 Hyperkeratosis Diseases 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 102000004877 Insulin Human genes 0.000 description 1
• 108090001061 Insulin Proteins 0.000 description 1
• 102100040018 Interferon alpha-2 Human genes 0.000 description 1
• 108010079944 Interferon-alpha2b Proteins 0.000 description 1
• 239000000232 Lipid Bilayer Substances 0.000 description 1
• 241000699666 Mus <mouse, genus> Species 0.000 description 1
• STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
• 239000004743 Polypropylene Substances 0.000 description 1
• 241000700159 Rattus Species 0.000 description 1
• 102000007562 Serum Albumin Human genes 0.000 description 1
• 108010071390 Serum Albumin Proteins 0.000 description 1
• 206010040880 Skin irritation Diseases 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• 229960004892 acemetacin Drugs 0.000 description 1
• FSQKKOOTNAMONP-UHFFFAOYSA-N acemetacin Chemical compound CC1=C(CC(=O)OCC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 FSQKKOOTNAMONP-UHFFFAOYSA-N 0.000 description 1
• 229920006243 acrylic copolymer Polymers 0.000 description 1
• 230000004913 activation Effects 0.000 description 1
• 230000006978 adaptation Effects 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 230000004931 aggregating effect Effects 0.000 description 1
• 230000001476 alcoholic effect Effects 0.000 description 1
• 238000004458 analytical method Methods 0.000 description 1
• 229940059312 androderm Drugs 0.000 description 1
• 230000001773 anti-convulsant effect Effects 0.000 description 1
• 230000002686 anti-diuretic effect Effects 0.000 description 1
• 239000001961 anticonvulsive agent Substances 0.000 description 1
• 229940124538 antidiuretic agent Drugs 0.000 description 1
• 239000003160 antidiuretic agent Substances 0.000 description 1
• 229960003965 antiepileptics Drugs 0.000 description 1
• 239000007900 aqueous suspension Substances 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• 238000010241 blood sampling Methods 0.000 description 1
• DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 229940063628 catapres Drugs 0.000 description 1
• 150000001783 ceramides Chemical class 0.000 description 1
• BHYOQNUELFTYRT-DPAQBDIFSA-N cholesterol sulfate Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 BHYOQNUELFTYRT-DPAQBDIFSA-N 0.000 description 1
• 229940080277 cholesteryl sulfate Drugs 0.000 description 1
• 239000007979 citrate buffer Substances 0.000 description 1
• 229960003120 clonazepam Drugs 0.000 description 1
• DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
• 238000009833 condensation Methods 0.000 description 1
• 230000005494 condensation Effects 0.000 description 1
• 239000000470 constituent Substances 0.000 description 1
• 239000000356 contaminant Substances 0.000 description 1
• 238000001816 cooling Methods 0.000 description 1
• 229940069235 cordran Drugs 0.000 description 1
• 230000008878 coupling Effects 0.000 description 1
• 238000010168 coupling process Methods 0.000 description 1
• 238000005859 coupling reaction Methods 0.000 description 1
• 230000007423 decrease Effects 0.000 description 1
• 230000018044 dehydration Effects 0.000 description 1
• 238000006297 dehydration reaction Methods 0.000 description 1
• 230000008021 deposition Effects 0.000 description 1
• 230000000368 destabilizing effect Effects 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 230000010339 dilation Effects 0.000 description 1
• 238000009510 drug design Methods 0.000 description 1
• 230000009977 dual effect Effects 0.000 description 1
• 229940099191 duragesic Drugs 0.000 description 1
• 238000002296 dynamic light scattering Methods 0.000 description 1
• 238000004520 electroporation Methods 0.000 description 1
• 229940074117 estraderm Drugs 0.000 description 1
• 210000001723 extracellular space Anatomy 0.000 description 1
• 238000013213 extrapolation Methods 0.000 description 1
• 229960002428 fentanyl Drugs 0.000 description 1
• 239000000835 fiber Substances 0.000 description 1
• 238000005429 filling process Methods 0.000 description 1
• 238000010579 first pass effect Methods 0.000 description 1
• 229920002457 flexible plastic Polymers 0.000 description 1
• 235000013305 food Nutrition 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 238000002695 general anesthesia Methods 0.000 description 1
• 210000003780 hair follicle Anatomy 0.000 description 1
• 238000004128 high performance liquid chromatography Methods 0.000 description 1
• 150000002433 hydrophilic molecules Chemical class 0.000 description 1
• 230000002706 hydrostatic effect Effects 0.000 description 1
• 239000005414 inactive ingredient Substances 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 229940125396 insulin Drugs 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 230000006662 intracellular pathway Effects 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• 230000007794 irritation Effects 0.000 description 1
• VCMGMSHEPQENPE-UHFFFAOYSA-N ketamine hydrochloride Chemical compound [Cl-].C=1C=CC=C(Cl)C=1C1([NH2+]C)CCCCC1=O VCMGMSHEPQENPE-UHFFFAOYSA-N 0.000 description 1
• 239000002502 liposome Substances 0.000 description 1
• 239000006166 lysate Substances 0.000 description 1
• 229920002521 macromolecule Polymers 0.000 description 1
• 239000003550 marker Substances 0.000 description 1
• 230000001404 mediated effect Effects 0.000 description 1
• 239000000155 melt Substances 0.000 description 1
• 239000004530 micro-emulsion Substances 0.000 description 1
• 239000012229 microporous material Substances 0.000 description 1
• 230000003020 moisturizing effect Effects 0.000 description 1
• 210000000214 mouth Anatomy 0.000 description 1
• 239000002105 nanoparticle Substances 0.000 description 1
• 229920005615 natural polymer Polymers 0.000 description 1
• 229960002715 nicotine Drugs 0.000 description 1
• SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
• 239000002353 niosome Substances 0.000 description 1
• 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 1
• 210000003463 organelle Anatomy 0.000 description 1
• 230000008520 organization Effects 0.000 description 1
• 239000000546 pharmaceutical excipient Substances 0.000 description 1
• XEBWQGVWTUSTLN-UHFFFAOYSA-M phenylmercury acetate Chemical compound CC(=O)O[Hg]C1=CC=CC=C1 XEBWQGVWTUSTLN-UHFFFAOYSA-M 0.000 description 1
• 229920001155 polypropylene Polymers 0.000 description 1
• 229920000136 polysorbate Polymers 0.000 description 1
• 229950008882 polysorbate Drugs 0.000 description 1
• 239000004800 polyvinyl chloride Substances 0.000 description 1
• 229920000915 polyvinyl chloride Polymers 0.000 description 1
• 239000005033 polyvinylidene chloride Substances 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 230000004845 protein aggregation Effects 0.000 description 1
• 230000017854 proteolysis Effects 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 229940069575 rompun Drugs 0.000 description 1
• 229960002646 scopolamine Drugs 0.000 description 1
• 230000036556 skin irritation Effects 0.000 description 1
• 231100000475 skin irritation Toxicity 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• 239000007787 solid Substances 0.000 description 1
• 238000007711 solidification Methods 0.000 description 1
• 230000008023 solidification Effects 0.000 description 1
• 238000000935 solvent evaporation Methods 0.000 description 1
• 238000000527 sonication Methods 0.000 description 1
• 238000001179 sorption measurement Methods 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 210000000952 spleen Anatomy 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 238000004659 sterilization and disinfection Methods 0.000 description 1
• 229920001059 synthetic polymer Polymers 0.000 description 1
• 230000008719 thickening Effects 0.000 description 1
• 229940035321 transderm scop Drugs 0.000 description 1
• 229940100640 transdermal system Drugs 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 230000001960 triggered effect Effects 0.000 description 1
• 238000009736 wetting Methods 0.000 description 1
• 210000002268 wool Anatomy 0.000 description 1
• QYEFBJRXKKSABU-UHFFFAOYSA-N xylazine hydrochloride Chemical compound Cl.CC1=CC=CC(C)=C1NC1=NCCCS1 QYEFBJRXKKSABU-UHFFFAOYSA-N 0.000 description 1